New polio vaccine shows promise in large infant trial
NCT ID NCT07297186
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 3 trial tested a new Sabin strain inactivated polio vaccine (sIPV) in 1200 healthy infants aged 2 months. The study compared the new vaccine to a standard polio vaccine to see if it was safe and triggered a strong immune response. The goal is to offer a more affordable and safer option to help eliminate polio worldwide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sabin strain inactivated poliovirus vaccine (sIPV)
What this could lead to
If successful, this could provide a safer and more affordable polio vaccine option for infants, helping global eradication efforts.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The vaccine may not be as effective as the current standard, or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLIOMYELITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, 210009, China